Vomiren 0.075 mg/1.5 ml (IV Injection)
1.5 ml ampoule: ৳ 75.00 (1 x 5: ৳ 375.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Palonosetron |
| Company | Renata limited |
| Also available as |
Title
- Vomiren
Categories
- Medicine
- Anti-emetic drugs
Description
- Palonosetron indicated for acute and delayed nausea and vomiting, uncontrolled nausea and vomiting, chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, post-operative & post-discharge nausea and vomiting
DosageAndAdministration
- Usual dosage: Adult tablet dosage - 0.5 mg daily, Adult IV dosage - 0.075 mg over 10 seconds
- Chemotherapy-induced nausea and vomiting: Adult tablet dosage - 0.5 mg approximately 1 hour prior to the start of chemotherapy, Adult IV dosage - 0.25 mg over 30 seconds approximately 30 minutes before the start of chemotherapy
- Radiotherapy-induced nausea and vomiting: A single IV dose of 0.25 mg over 30 seconds approximately 30 minutes before each week of radiation fraction
- Post-operative nausea and vomiting: A single IV dose of 0.075 mg over 10 seconds immediately before induction of anesthesia
- Children dosage: A single IV dose at 20 mcg/kg body weight with a maximum dose of 1.5 mg
Indications
- Acute and delayed nausea and vomiting
- Uncontrolled nausea and vomiting
- Chemotherapy-induced nausea and vomiting
- Radiotherapy-induced nausea and vomiting
- Post-operative & post-discharge nausea and vomiting
Pharmacology
- 5-HT3 receptor antagonist
- Binds strongly to 5-HT3 receptor
- Little or no affinity for other receptors
- Blocks the actions of serotonin
- Works in small intestine and may also work in the brain
Interaction
- Safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics, anticholinergic agents
- No significant pharmacokinetic interactions with metoclopramide
- Not an inhibitor of CYP enzymes
Contraindications
- Hypersensitivity to the drug or any of its components
SideEffects
- Headaches
- Constipation
PregnancyAndLactation
- Pregnancy category 'B'
- Not known if excreted in breast milk
SpecialPopulations
- No dosage adjustment recommended in elderly patients >65 years of age
- No dosage adjustment recommended in patients with renal and hepatic dysfunction
OverdoseEffects
- No known antidote
- Manage with supportive care
StorageConditions
- Store in a cool & dry place, protected from light
TechnicalSpecifications
- DoseRange: 1-90 μg/kg
- MeanMaxPlasmaConcentration: 0.89 to 336 ng/ml
- AreaUnderCurve: 13.8 to 957 ng.h/ml
- VolumeOfDistribution: 6.9-7.9 L/kg
- PlasmaProteinBinding: Approximately 62%
- Metabolism: 50% via kidney, 50% by liver CYP2D6, CYP3A4, and CYP1A2 isoenzymes
- Excretion: Approximately 40% as unchanged drug in the urine after 144 hours
- TotalBodyClearance: 160±35 ml/h/kg
- HalfLife: 40 hours